Arvinas (ARVN) Competitors $8.11 -0.02 (-0.30%) As of 09:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARVN vs. VCEL, CNTA, DNLI, KYMR, GMTX, MIRM, ARWR, BLTE, CGON, and HRMYShould you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Vericel (VCEL), Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), Kymera Therapeutics (KYMR), Gemini Therapeutics (GMTX), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), Belite Bio (BLTE), CG Oncology (CGON), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Arvinas vs. Vericel Centessa Pharmaceuticals Denali Therapeutics Kymera Therapeutics Gemini Therapeutics Mirum Pharmaceuticals Arrowhead Pharmaceuticals Belite Bio CG Oncology Harmony Biosciences Arvinas (NASDAQ:ARVN) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk. Does the MarketBeat Community believe in ARVN or VCEL? Vericel received 159 more outperform votes than Arvinas when rated by MarketBeat users. However, 66.55% of users gave Arvinas an outperform vote while only 61.78% of users gave Vericel an outperform vote. CompanyUnderperformOutperformArvinasOutperform Votes19566.55% Underperform Votes9833.45% VericelOutperform Votes35461.78% Underperform Votes21938.22% Does the media refer more to ARVN or VCEL? In the previous week, Arvinas had 5 more articles in the media than Vericel. MarketBeat recorded 14 mentions for Arvinas and 9 mentions for Vericel. Vericel's average media sentiment score of 1.71 beat Arvinas' score of 0.77 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals and insiders hold more shares of ARVN or VCEL? 95.2% of Arvinas shares are held by institutional investors. 5.2% of Arvinas shares are held by company insiders. Comparatively, 5.2% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, ARVN or VCEL? Arvinas has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Is ARVN or VCEL more profitable? Vericel has a net margin of 1.56% compared to Arvinas' net margin of -75.51%. Vericel's return on equity of 1.48% beat Arvinas' return on equity.Company Net Margins Return on Equity Return on Assets Arvinas-75.51% -33.75% -16.75% Vericel 1.56%1.48%0.96% Which has better valuation & earnings, ARVN or VCEL? Vericel has lower revenue, but higher earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArvinas$263.40M2.12-$198.90M-$2.77-2.94Vericel$237.22M10.10-$3.18M$0.18266.44 Do analysts prefer ARVN or VCEL? Arvinas currently has a consensus target price of $35.50, suggesting a potential upside of 336.65%. Vericel has a consensus target price of $62.29, suggesting a potential upside of 29.87%. Given Arvinas' higher probable upside, equities research analysts plainly believe Arvinas is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arvinas 0 Sell rating(s) 5 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.67Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryVericel beats Arvinas on 10 of the 18 factors compared between the two stocks. Remove Ads Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARVN vs. The Competition Export to ExcelMetricArvinasPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$559.12M$6.99B$5.68B$8.30BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-2.947.2324.5519.25Price / Sales2.12230.77395.7294.10Price / CashN/A65.6738.1634.64Price / Book1.006.617.064.46Net Income-$198.90M$142.13M$3.19B$247.07M7 Day Performance-6.55%1.72%0.18%1.77%1 Month Performance-52.39%2.31%5.53%-3.31%1 Year Performance-80.17%-5.07%14.21%5.26% Arvinas Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARVNArvinas3.366 of 5 stars$8.11-0.3%$35.50+337.9%-80.0%$557.47M$263.40M-2.93420Gap UpVCELVericel2.7228 of 5 stars$47.36+4.4%$62.29+31.5%+0.0%$2.36B$237.22M785.76300Positive NewsCNTACentessa Pharmaceuticals2.3505 of 5 stars$17.41+1.6%$26.00+49.3%+37.4%$2.29B$6.85M-11.38200Earnings ReportUpcoming EarningsAnalyst RevisionNews CoverageDNLIDenali Therapeutics4.3622 of 5 stars$15.47+2.1%$37.20+140.4%-28.9%$2.25B$330.53M-5.61430Positive NewsKYMRKymera Therapeutics1.3467 of 5 stars$34.45+0.2%$56.36+63.6%-19.4%$2.24B$47.07M-14.72170Positive NewsGMTXGemini TherapeuticsN/A$51.02-2.7%N/A-9.7%$2.21BN/A-51.0230Positive NewsMIRMMirum Pharmaceuticals4.0481 of 5 stars$44.71+1.0%$58.20+30.2%+80.0%$2.19B$336.89M-22.14140Positive NewsARWRArrowhead Pharmaceuticals3.7961 of 5 stars$15.75+2.5%$41.44+163.2%-47.2%$2.16B$2.50M-3.04400BLTEBelite Bio2.1629 of 5 stars$67.42-0.1%$96.33+42.9%+47.4%$2.15BN/A-60.7310Gap DownCGONCG Oncology1.8286 of 5 stars$27.58-0.8%$63.88+131.6%-32.4%$2.10B$684,000.000.0061Analyst ForecastNews CoverageHRMYHarmony Biosciences4.2968 of 5 stars$34.23+4.6%$53.11+55.2%+1.2%$1.96B$714.73M16.22200 Remove Ads Related Companies and Tools Related Companies VCEL Competitors CNTA Competitors DNLI Competitors KYMR Competitors GMTX Competitors MIRM Competitors ARWR Competitors BLTE Competitors CGON Competitors HRMY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARVN) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARVN Stock Free ARVN Stock Alerts